Darovasertib

Darovasertib (IDE196, LXS196) is a small-molecule drug developed by IDEAYA Biosciences. The sponsor describes its target as PKC (protein kinase C), which OnCo does not yet have a target page for. The sponsor states: Darovasertib is a small-molecule PKC inhibitor targeting the oncogenic driver of uveal melanoma associated with GNAQ/GNA11 mutations or PRKC fusions. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07804186 (Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma) and NCT07015190 (Neoadjuvant Darovasertib in Primary Uveal Melanoma), in uveal melanoma and melanoma. The largest, NCT07015190, plans to enrol 520 participants with primary completion expected 2030-10. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.